news

한어Русский языкEnglishFrançaisIndonesianSanskrit日本語DeutschPortuguêsΕλληνικάespañolItalianoSuomalainenLatina

【Performance】

Yisheng shares: In July, the sales revenue of white-feathered broiler chicks was 188 million yuan, a year-on-year decrease of 14.77%.

Yisheng Shares (002458) announced on the evening of August 11 that the sales volume of white-feathered broiler chicks in July was 52.9819 million, with sales revenue of 188 million yuan, a year-on-year change of -11.14% and -14.77%, and a month-on-month change of 2.69% and 25.23% respectively. The sales volume of breeding pigs in July was 551, with sales revenue of 1.0942 million yuan, a year-on-year change of 533.33% and 143.94%, and a month-on-month change of -67.87% and -75.43% respectively.

Netda Software: Net profit of 6.006 million yuan in the first half of the year, turning losses into profits year-on-year

Netda Software (603189) released its semi-annual report on the evening of August 11, achieving operating income of 178 million yuan in the first half of the year, a year-on-year increase of 22.13%; net profit attributable to shareholders of the listed company was 6.006 million yuan, a year-on-year turnaround from a loss of 35.5716 million yuan in the same period last year; basic earnings per share was 0.02 yuan. During the reporting period, the company's personnel costs decreased compared with the same period last year, and its cost control ability was further enhanced; the company actively promoted project acceptance, and revenue recognition increased; the company strengthened cash and accounts receivable management, and the collection situation was good, and the impairment provision for the same period decreased.

Xiangfenghua: Net profit in the first half of the year decreased by 44.92% year-on-year

Xiangfenghua (300890) released its semi-annual report on the evening of August 11, with operating income of 707 million yuan in the first half of the year, a year-on-year decrease of 28.75%; net profit attributable to shareholders of listed companies was 38.2408 million yuan, a year-on-year decrease of 44.92%; basic earnings per share was 0.3497 yuan. The decline in revenue was mainly due to the slowdown in the growth of the company's downstream industry, the continuous growth of negative electrode material production capacity, the periodic imbalance of the supply and demand environment, and the intensified competition among industry enterprises, which led to a decline in product unit prices during the reporting period.

Xianle Health: Net profit in the first half of the year increased by 52.66% year-on-year

Xianle Health (300791) released its semi-annual report on the evening of August 11, achieving operating income of 1.99 billion yuan in the first half of the year, a year-on-year increase of 28.85%; net profit attributable to shareholders of listed companies was 154 million yuan, a year-on-year increase of 52.66%; basic earnings per share was 0.86 yuan.

【Contract Winning Bid】

Minsheng Health: Signing a strategic cooperation intention agreement in the field of probiotics

Minsheng Health (301507) announced on the evening of August 11 that the company (Party A) signed a "Strategic Cooperation Intention Agreement" with Pan Yulin (Party B 1) and Zhongke Jiayi (Shandong) Investment Holding Co., Ltd. (Party B 2). Both parties agreed that Party B 2, as the controlling shareholder, would invest in the establishment of a limited liability company (hereinafter referred to as the "Target Company") as the entity responsible for the research and development, production and sales of probiotic raw materials and related finished products. After the prerequisites agreed in this agreement are met, Party A intends to exchange 45% of the equity of its wholly-owned subsidiary Health Technology for 100% of the equity of the Target Company from the shareholders of the Target Company. Before the exchange, Party A agreed to increase capital in Health Technology. After the transaction is completed, the Target Company will become a wholly-owned subsidiary of Health Technology.

Huifeng Shares: Subsidiary signs cooperation agreement for green mine hydrogen energy mining demonstration project

Huifeng Co., Ltd. (002496) announced on the evening of August 11 that its wholly-owned subsidiary Huifeng Petrochemical (hereinafter referred to as "Party B") and Magang Mining (hereinafter referred to as "Party A") recently signed the "Green Mine Hydrogen Energy Mining Area Demonstration Project Cooperation Agreement" to jointly build the "Green Mine Hydrogen Energy Mining Area". After the government's administrative approval, Party B will first invest 40 million to 50 million yuan in the first phase of the project to build two sets of 1000kg/d ammonia hydrogen production and hydrogenation demonstration projects. After the construction is completed and the trial operation period expires, after the local government functional departments and Party A review and approval, Party B can gradually increase the hydrogen energy mining truck transportation vehicles and conduct a joint trial operation.

Dashi Intelligent: Guangna Building project signed

Dashi Intelligent (002421) announced on the evening of August 11 that the company and Inner Mongolia Guangna Coal Industry (Group) Co., Ltd. reached an agreement on the Guangna Building Intelligentization Project and formally signed a project contract with a contract amount of RMB 10.5 million, accounting for 0.27% of the company's audited operating income in 2023. The company will rely on its rich experience accumulated in the field of smart buildings over the years to provide users with overall solutions for smart spaces.

【Changes in equity】

Daqian Ecology: The company's control change has been terminated

Daqian Ecology (603955) announced on the evening of August 11 that it had previously announced that its controlling shareholder Daqian Investment intended to transfer its 17.09% stake in the company to Tiansheng Yihe by agreement, and this transaction would result in a change in the company's control. The company received a notice from Daqian Investment that the parties to the transaction signed the "Termination Agreement of the <Share Transfer Agreement>" on August 11. After the termination of this agreement transfer, the company's controlling shareholder is still Daqian Investment, and the actual controller is still Luan Jianhong and Fan Hedi.

【other】

United Optoelectronics: Plans to transfer part of the equity of its subsidiary to implement equity incentives

United Optoelectronics (300691) announced on the evening of August 11 that its subsidiary United Automotive intends to implement equity incentives. The equity incentives will be obtained through equity transfers, and the incentive recipients will participate in this equity incentive by indirectly holding United Automotive shares through a limited partnership (employee shareholding platform). Chengdu Lianjiang, a second-level wholly-owned subsidiary of the company, intends to transfer its 66.66% equity in Ruijin Technology directly held by it to two employee shareholding platforms for a total price of RMB 22.8571 million. Since Ruijin Technology is only a shareholding platform and does not carry out other business operations, this transaction ultimately enables the two employee shareholding platforms to indirectly hold 20% of the equity of United Automotive through holding Ruijin Technology.

Huaren Pharmaceutical: The listing application of pentoxifylline API of its wholly-owned subsidiary was approved

Huaren Pharmaceutical (300110) announced on the evening of August 11 that its wholly-owned subsidiary Anhui Hengxing Pharmaceutical received the "Notice of Approval of Chemical API Marketing Application" for "Pentoxifylline API" approved and issued by the State Food and Drug Administration. Pentoxifylline is indicated for peripheral arterial disease (intermittent claudication or rest pain) and inner ear circulatory disorders.

Jiudian Pharmaceutical: Withdrawal of drug registration application for Jiaoqishe Gel Patch

Jiudian Pharmaceutical (300705) announced on the evening of August 11 that due to the need to further improve relevant test data, the company recently submitted a report to withdraw the drug registration application for Jiaoqishe Gel Patch to the State Food and Drug Administration.

Sinopharm Modern Pharmaceuticals: Cefuroxime Sodium for Injection of its Holding Subsidiary Passed the Generic Drug Consistency Evaluation

Sinopharm Modern Pharmaceuticals (600420) announced on the evening of August 11 that its holding subsidiary Sinopharm Zhijun received the "Notice of Approval of Supplementary Drug Application" approved and issued by the State Drug Administration, approving the passing of the generic drug quality and efficacy consistency evaluation (hereinafter referred to as consistency evaluation) for Cefuroxime Sodium for Injection. Cefuroxime Sodium for Injection is suitable for lower respiratory tract infections, urinary tract infections, abdominal infections, pelvic infections, etc. caused by sensitive bacteria.

Hengrui Medicine: Paclitaxel for Injection (Albumin-bound) Receives Approval Notice for Supplementary Drug Application

Hengrui Medicine (600276) announced on the evening of August 11 that it had received the "Notice of Approval of Supplementary Drug Application" for Paclitaxel for Injection (Albumin-bound) from the National Medical Products Administration. In addition to the approved indications, the drug has a new indication of "suitable for combination with gemcitabine as first-line treatment for metastatic pancreatic cancer."

Maiwei Bio: 9MW2821 for urothelial carcinoma is included in the breakthrough therapy category

Mywell Biopharmaceuticals (688062) announced on the evening of August 11 that its innovative drug 9MW2821 was recently included in the list of breakthrough therapies by the Center for Drug Evaluation of the National Medical Products Administration for the treatment of locally advanced or metastatic urothelial carcinoma that has failed previous platinum chemotherapy and PD-(L)1 inhibitor treatments, and has been publicly announced.

Editor: Chen Lixiang

Proofreading: Yao Yuan

The 18th China Listed Company Value Selection Event hosted by Securities Times has officially entered the public voting stage!The voting period is from August 8th to August 18th.

Investors are welcome to vote for the outstanding listed companies or listed company executives in your minds.

For more event details, please follow "e Company".